Two-Drug combo may boost vision in diabetic eye disease
NCT ID NCT07438119
First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This study compares a combination of a steroid implant (dexamethasone) plus an anti-VEGF injection (aflibercept) against aflibercept alone for diabetic macular edema. Researchers will enroll 114 people with diabetes who have not had prior treatment. The goal is to see if the combo improves vision and reduces retinal swelling more than the standard single drug.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- Dexamethasone intravitreal implant (steroid) combined with aflibercept injection (anti-VEGF)
- What this could lead to
- If successful, this combination could offer better vision outcomes for people with diabetic macular edema who have signs of inflammation.
- What could go wrong
- This is a Phase 4 study that hasn't started yet, with only 114 participants. The combination may not prove superior and carries risks like increased eye pressure or cataract from the steroid.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for DIABETIC MACULAR EDEMA (DME) are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can a new eye injection beat the current standard for diabetic vision loss?
- AI could predict which eye treatments work best for Diabetes-Related vision loss
- New eye drug EYE103 takes on lucentis in major trial for Diabetes-Related vision loss
- New dosing strategy could mean fewer eye injections for Diabetes-Related vision loss
- New syringe could simplify High-Dose eye treatment
- Eye scan showdown: faricimab vs ranibizumab in diabetic retinopathy